Dabogratinib (Synonyms: TYRA-300)

Name: Dabogratinib
Brand: MedChemExpress
SKU: HY-159642
Rating: 4.5 (1 reviews)

Cat. No.: HY-159642 Purity: 99.90%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Dabogratinib (TYRA-300) is an orally active, selective FGFR3 inhibitor with an IC₅₀ of 11 nM. Dabogratinib exhibits antitumor activity against urothelial carcinoma and solid tumors. Dabogratinib downregulates the FGFR3 and ERK1/2 signaling pathways, and induces tumor growth inhibition and regression in FGFR3-altered xenograft models. Dabogratinib promotes chondrocyte proliferation and differentiation, drives endochondral bone formation and overall body growth, partially restores long bone proportions, and improves craniofacial and spinal morphology. Dabogratinib can be used for the research of metastatic urothelial carcinoma, achondroplasia and hypochondroplasia.

For research use only. We do not sell to patients.

Dabogratinib Chemical Structure

CAS No. : 2800223-30-5

Size	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
1 mg	In-stock	Estimated Time of Arrival: December 31
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
25 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	In-stock	Estimated Time of Arrival: December 31
100 mg	In-stock	Estimated Time of Arrival: December 31
200 mg	Get quote
500 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of Dabogratinib:

Dabogratinib (GMP) Get quote

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All ERK Isoform Specific Products:

View All Isoforms

ERK ERK1 ERK2 ERK5 ERK8

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target^[3]

FGFR3

11 nM (IC₅₀)

FGFR2

157 nM (IC₅₀)

FGFR1

278 nM (IC₅₀)

FGFR4

4045 nM (IC₅₀)

Cellular Effect

Cell Line	Type	Value	Description	References
DMS-114	IC₅₀	205 nM Compound: 22	Inhibition of cell viability in human DMS-114 cells harboring FGFR1-amplification incubated for 72 to 120 hrs by Cell Titer Glo assay Inhibition of cell viability in human DMS-114 cells harboring FGFR1-amplification incubated for 72 to 120 hrs by Cell Titer Glo assay	[PMID: 39258897]
KG-1	IC₅₀	109 nM Compound: 22	Inhibition of cell viability in human KG-1 cells harboring FGFR1-fusion incubated for 72 to 120 hrs by Cell Titer Glo assay Inhibition of cell viability in human KG-1 cells harboring FGFR1-fusion incubated for 72 to 120 hrs by Cell Titer Glo assay	[PMID: 39258897]
RT-4	IC₅₀	10 nM Compound: 22	Inhibition of cell viability in human RT-4 cells harboring FGFR3/TACC3 fusion incubated for 72 to 120 hrs by Cell Titer Glo assay Inhibition of cell viability in human RT-4 cells harboring FGFR3/TACC3 fusion incubated for 72 to 120 hrs by Cell Titer Glo assay	[PMID: 39258897]

In Vitro

Dabogratinib (0.046 nM-3 μM; 2 h) induces dose-dependent downregulation of the FGFR3 downstream signaling pathway (assessed by pERK1/2 levels) in RT112/84, RT112/84-V555M and UM-UC-14 bladder cancer cell lines^[1].
Dabogratinib inhibits the viability of FGFR3-driven bladder cancer cell lines, with IC₅₀ values of 9 nM for the RT112/84 cell line, 17 nM for the RT112/84-V555M cell line, and 16 nM for the UM-UC-14 cell line^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[1]

Cell Line:	RT112/84, RT112/84-V555M, and UM-UC-14 bladder cancer cell lines
Concentration:	0.046, 0.18, 0.73, 2.9, 12, 47, 188, 750, 3000 nM
Incubation Time:	2 hours
Result:	Induced a dose-dependent decrease in pERK1/2 levels in all three cell lines; showed similar dose-response patterns in gatekeeper-mutant RT112/84-V555M cell line as in RT112/84 and UM-UC-14 cell lines harboring only activating alterations.

In Vivo

Dabogratinib (3-18 mg/kg; p.o.; twice/once daily; 21 days) exhibits dose-dependent in vivo efficacy in urothelial carcinoma xenograft models harboring FGFR3^S249C^[1].
Dabogratinib (12.5 mg/kg; p.o.; twice daily) induces tumor regression in FGFR3::TACC3 fusion urothelial carcinoma xenograft models and FGFR3V555M urothelial carcinoma xenograft models^[1].
Dabogratinib (8-14 mg/kg; p.o.; once daily; 4 weeks) dose-dependently increases the growth rate of wild-type mice and promotes their long bone growth in vivo^[2].
Dabogratinib (1.2 mg/kg; s.c.; once daily; 15 days) promotes bone growth, improves skeletal proportions, optimizes growth plate structure, and increases the foramen magnum size in the Fgfr3^Y367C/+ mouse model of achondroplasia (ACH)^[2].
Dabogratinib (1.8 mg/kg; s.c.; once daily; 21 days) increases bone length, enlarges foramen magnum size and improves intervertebral disc morphology in the Fgfr3^N534K/+ mouse model of HCH^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	athymic nude (nu/nu) (female, 6 to 8 weeks old)^[1]
Dosage:	3, 6 and 9 mg/kg (twice daily); 6, 12 and18 mg/kg (once daily)
Administration:	p.o.; twice daily; 21 days; p.o.; once daily; 21 days
Result:	Observed no tumor growth inhibition (TGI) at 3 mg/kg twice daily; Achieved 53% TGI at 6 mg/kg twice daily, 90% TGI at 9 mg/kg twice daily, 46% TGI at 6 mg/kg once daily, 80% TGI at 12 mg/kg once daily, and 96% TGI at 18 mg/kg once daily. Detected significant tumor volume reduction with 12, 18 mg/kg once daily and 9 mg/kg twice daily compared with vehicle. Observed more tumor regression with 18 mg/kg once daily than erdafitinib 12.5 mg/kg twice daily. Recorded no body weight loss in any treatment group.

Animal Model:	C57BL/6J (female, 4-8 weeks of age)^[2]
Dosage:	8, 10, 12, 14 mg/kg
Administration:	p.o.; once daily; 4 weeks
Result:	Increased nasoanal length by 7.3% with 14 mg/kg compared with vehicle; increased tibia length by 3.9% and femur length by 5.0% with 12 mg/kg compared with vehicle. Increased tibia length by 6.4% and femur length by 8.2% with 14 mg/kg compared with vehicle. Induced significant increases in nasoanal length, tibia length, and femur length with 8 mg/kg and 10 mg/kg compared with vehicle.

Animal Model:	Tg-CMV^Cre/+ / Fgfr3^Y367C/+ (mixed male and female, 1 day of age, Achondroplasia modeling)^[2]
Dosage:	1.2 mg/kg
Administration:	s.c.; once daily; 15 days
Result:	Increased nasoanal length by 17.88%, tail length by 25.10%, and body weight by 52.9% compared with vehicle-treated mutant mice; increased tibia length by 33.01%, femur length by 22.55%, ulna length by 23.51%, and humerus length by 15.52% compared with vehicle. Increased skull length by 10.08%, skull width by 3.74%, skull anteroposterior length by 8.92%, and skull nasio-occipital length by 7.87% compared with vehicle; increased foramen magnum transverse diameter by 13.05%, sagittal diameter by 9.28%, and area by 25.17% compared with vehicle. Improved the grade of skull base synchondroses, increased the size of hypertrophic zone chondrocytes (HZCs), increased proliferation of proliferating zone chondrocytes (PZCs), increased bone mineral density (BMD) by 21.4%, and increased bone volume-to-tissue volume ratio (BV/TV) by 73.3% compared with vehicle; increased L4-L6 lumbar vertebrae segment length by 23.49% compared with vehicle.

Animal Model:	Tg-CMV^Cre/+ / Fgfr3^N534K/+ (mixed male and female, 3 days of age, Hypochondroplasia modeling)^[2]
Dosage:	1.8 mg/kg
Administration:	s.c.; once daily; 21 days
Result:	Increased femur length by 3.70%, tibia length by 3.75%, ulna length by 5.03%, and humerus length by 3.22% compared with vehicle-treated mutant mice. Increased foramen magnum area by 7.51% and sagittal diameter by 6.35% compared with vehicle; reduced the grade of skull base synchondroses from grade V (completely fused) to grade IV (completely fused with cartilage margin remnants) in most mice and improved intervertebral disc shape compared with vehicle.

Molecular Weight

559.47

Formula

C₂₅H₂₄Cl₂N₆O₃S

CAS No.

2800223-30-5

Appearance

Solid

Color

White to off-white

SMILES

O=S(N(C1)CC1(C2)CN2C(N=C3)=CC=C3C4=NNC5=CC=C(O[C@H](C)C6=C(Cl)C=NC=C6Cl)C=C54)(C)=O

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (178.74 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.7874 mL	8.9370 mL	17.8741 mL
5 mM	0.3575 mL	1.7874 mL	3.5748 mL
10 mM	0.1787 mL	0.8937 mL	1.7874 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 5 mg/mL (8.94 mM); Clear solution

This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 5 mg/mL (8.94 mM); Clear solution

This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.90%

Select Batch:

Data Sheet (284 KB) SDS (254 KB)

COA (256 KB) HNMR (275 KB) RP-HPLC (243 KB) LCMS (103 KB)

Handling Instructions (2659 KB)

References

[1]. Starrett JH, et al. Dabogratinib (TYRA-300), an FGFR3 isoform-selective inhibitor: preclinical and initial clinical evidence of anti-tumor activity. Mol Cancer Ther. Published online October 14, 2025. [Content Brief]

[2]. Starrett JH, et al. TYRA-300, an FGFR3-selective inhibitor, promotes bone growth in two FGFR3-driven models of chondrodysplasia. JCI Insight. 2025;10(9):e189307. Published 2025 Apr 3. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	1.7874 mL	8.9370 mL	17.8741 mL	44.6852 mL
	5 mM	0.3575 mL	1.7874 mL	3.5748 mL	8.9370 mL
	10 mM	0.1787 mL	0.8937 mL	1.7874 mL	4.4685 mL
	15 mM	0.1192 mL	0.5958 mL	1.1916 mL	2.9790 mL
	20 mM	0.0894 mL	0.4469 mL	0.8937 mL	2.2343 mL
	25 mM	0.0715 mL	0.3575 mL	0.7150 mL	1.7874 mL
	30 mM	0.0596 mL	0.2979 mL	0.5958 mL	1.4895 mL
	40 mM	0.0447 mL	0.2234 mL	0.4469 mL	1.1171 mL
	50 mM	0.0357 mL	0.1787 mL	0.3575 mL	0.8937 mL
	60 mM	0.0298 mL	0.1490 mL	0.2979 mL	0.7448 mL
	80 mM	0.0223 mL	0.1117 mL	0.2234 mL	0.5586 mL
	100 mM	0.0179 mL	0.0894 mL	0.1787 mL	0.4469 mL

Dabogratinib Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Your Recently Viewed Products:

Product Name

Requested Quantity *

Applicant Name *

Salutation

Email Address *

Phone Number *

Department

Organization Name *

City

State

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *

Organization Name *

Country or Region *

Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

Dabogratinib (Synonyms: TYRA-300)

Customer Review

Other Forms of Dabogratinib:

Dabogratinib Related Antibodies

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All ERK Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

Dabogratinib Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Dabogratinib Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report